Hasil Pencarian - Collin M. Blakely

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

    Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC oleh Matthew S. Lara, BS, Matthew A. Gubens, MD, Bianca Bacaltos, MS, Lea Daran, BA, Steffany L. Lim, BS, Tianhong Li, MD, David R. Gandara, MD, Trever G. Bivona, MD, PhD, Jonathan W. Riess, MD, Collin M. Blakely, MD, PhD

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

    NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer oleh Collin M. Blakely, Evangelos Pazarentzos, Victor Olivas, Saurabh Asthana, Jenny Jiacheng Yan, Irena Tan, Gorjan Hrustanovic, Elton Chan, Luping Lin, Dana S. Neel, William Newton, Kathryn L. Bobb, Timothy R. Fouts, Jeffrey Meshulam, Matthew A. Gubens, David M. Jablons, Jeffrey R. Johnson, Sourav Bandyopadhyay, Nevan J. Krogan, Trever G. Bivona

    Diterbitkan 2015-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer oleh Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S.W. Tan, Rafael Rosell, Ross A Okimoto, Trever G. Bivona

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

    Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study oleh Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

    Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study oleh James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

    Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer oleh Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling oleh Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: